MSGS Stock Today: March 9 – Hedge Funds Trim Stakes, Insider Sale

We review MSGS stock today after fresh signals from hedge fund selling and an insider trade. Quantbot cut exposure, Gamco trimmed slightly, and Director Charles P. Dolan sold shares in February. That follows a powerful rally and rising attention on the Knicks and Rangers asset story. We break down price action, fundamentals, MSGS analyst ratings, and scenarios Australian investors should consider, including volatility and FX impacts when trading US equities from AUD accounts.

Hedge fund and insider activity

Quantbot reduced its MSGS position by 52% and Gamco trimmed 1.3% in Q3 disclosures. These moves can signal profit taking after a strong run. They may also cool near-term momentum if other funds follow. See the reported changes from Quantbot source and Gamco source.

Director Charles P. Dolan sold 5,659 shares in February. Insider selling can reflect diversification, taxes, or a view that gains have been realised. It is not always bearish on its own, yet coming alongside hedge fund selling, it can cap upside near term. We watch for follow-on Form 4s and whether selling broadens across the board.

Price, trend, and levels to watch

At the last reported close, MSGS stock was $313.34, down 1.6% on the day, with a range of $312.86 to $317.62. The 52-week range is $173.26 to $345.46. The 50-day average is $286.58 and the 200-day is $229.27, showing an established uptrend. RSI sits near 55.7, while ADX above 40 indicates a strong trend, though momentum has cooled.

Average True Range is 11.19, pointing to wide daily swings. Volume was 156,411 versus a 233,026 average, a lighter day that may reduce follow-through. Bollinger middle band is 308.96, a reference pivot. Upper and lower bands are 349.50 and 268.42. The Keltner middle at 310.68 aligns with nearby support. A push above 317.62 would help bulls.

Fundamentals and valuation check

EPS is -0.68 with a net margin near -1.55%. Current ratio is 0.47, showing tight liquidity. Net debt to EBITDA is roughly 107x and interest coverage is 0.21x, indicating heavy leverage relative to cash flow. Book value per share is negative, which makes balance sheet metrics less useful for classic value screens. Execution and asset value remain the thesis drivers.

Price-to-sales is 7.06x and EV-to-sales is 8.87x, both rich for the entertainment sector. P/E is not meaningful with negative earnings. Price to free cash flow near 2,738x underscores how much is priced into team asset optionality relative to cash generation. With limited dividends and thin free cash flow, sentiment shifts can move the stock quickly.

Street views, forecasts, and playbook

Street data shows 7 Buys and 2 Holds, with an aggregate score around 3.0 on a Hold scale. A separate quant model on 6 March 2026 rated the company C- with a Strong Sell stance, while another composite grade showed B+ and a BUY suggestion. Mixed signals suggest sizing carefully and waiting for high-conviction entries.

Hedge fund selling and insider activity raise odds of consolidation. Model forecasts point to $307.2 monthly, $318.33 quarterly, and $242.47 over a year, with longer horizons near $190. Earnings are scheduled for 1 May 2026 UTC. For Australian investors, watch USD exposure, fees, and after-hours liquidity when planning orders and stops.

Final Thoughts

MSGS stock rallied hard into 2026, but stake reductions by Quantbot and Gamco plus an insider sale could slow momentum. Price now sits above the 50- and 200-day averages, with ADX showing trend strength and Bollinger mid-band near $309 as a tactical pivot. Fundamentals remain cash flow light and leverage heavy, so the story leans on the Knicks and Rangers asset case. With split signals across models and MSGS analyst ratings, we see a buy-the-dip approach only at defined support, tight position sizing, and clear risk limits. Australian investors should also factor USD volatility and trading costs, and track filings, team performance, media updates, and the 1 May earnings date.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.